Health Newstrack

Track health news daily at HealthNewstrack.com

"herceptin"

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient’s outcome after treatment for HER2 Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

An investigational combination of TYKERB (lapatinib) plus HERCEPTIN (trastuzumab) proved a median survival of 14 months in women with an aggressive form of breast cancer. The results of the Phase III study in ErbB2-positive metastatic breast cancer were…


Using Herceptin with chemotherapy clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher. Patients using Herceptin and chemotherapy at the same time had a relative…


Cancer researchers are turning to mathematical models to help answer important clinical questions, and a new paper in Cancer Research, a journal of the American Association for Cancer Research, illustrates how the technique may answer questions about Herceptin resistance.


A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously…


Breast cancer is the second leading cause of cancer-related death among women. About 20 percent of women diagnosed with breast cancer are HER2-positive. The Inform Dual ISH test allows lab personnel to count the number of copies of HER2…


Life Technologies Corporation (NASDAQ: LIFE) announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple…


Researchers have identified a gene that is overexpressed in up to 20 percent of breast cancers and that could be blocked in the lab by a currently available blood pressure drug, according to a new study from the University…


A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies. Published in the July 1, 2009 issue of CANCER, a peer-reviewed journal…


Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO),…

1 2

Footer